News
Network Meta-Analysis Compares DOACs to LMWH for Cancer-Linked Thrombosis
Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban
Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin
Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban